Visão geral da empresa
A biopharmaceutical enterprise dedicated to the development and commercialization of therapeutic medicines for neurological and rare disease indications within the North American market. ACADIA Pharmaceuticals Inc. operates within the Healthcare sector, specifically inside the Biotechnology industry, a classification that signifies a focus on innovative drug discovery and high-risk, high-reward research and development activities. The company demonstrates a substantial operational footprint with 796 employees and a market capitalization of $3.85B, supported by a trailing twelve-month revenue of $1.07B. These financial figures indicate that the entity possesses a significant scale relative to many smaller biotech peers, suggesting established commercialization capabilities and a robust pipeline that has generated over a billion dollars in annual sales.
Saúde financeira
The company reported a revenue of $1.07B and a net income of $391.00M over the trailing twelve months, while EBITDA stood at $116.57M. The substantial gap between the $1.07B revenue and the $391.00M net income reveals a cost structure where operating expenses, including cost of goods sold and general administrative costs, consumed approximately 63.5% of total revenue before interest and taxes. Free cash flow is reported at $-54,821,124, which indicates that despite generating significant accounting profit, the company is currently burning cash, likely due to heavy reinvestment in clinical trials or commercial expansion. The gross margin sits at 61.0%, reflecting high pricing power and efficient manufacturing relative to the cost of production for their specialty medicines. The operating margin is 6.1%, suggesting that after covering operating expenses, the company retains a modest portion of revenue, while the profit margin of 36.5% highlights the significant impact of non-operating items or tax benefits on the bottom line. On the balance sheet, the company holds $819.69M in cash against $52.19M in debt, resulting in a debt-to-equity ratio of 4.25, which indicates a leveraged position where equity is the primary source of capitalization relative to debt obligations. The current ratio of 3.83 suggests a very strong short-term liquidity position, as the company holds nearly four times more current assets than current liabilities, ensuring it can comfortably meet its immediate financial obligations. Return on Equity is 39.9%, demonstrating highly effective management in generating profits from shareholders' equity, whereas the return on assets is 4.8%, indicating that the total asset base generates a moderate return on the capital employed to run the business.
Avaliação de valorização
The trailing P/E ratio is 9.81, while the forward P/E is 24.52, implying that the market expects earnings to grow significantly in the future to justify the higher multiple projected for the coming year. The price-to-book ratio stands at 3.13, indicating that the market values the company at a premium of over three times its net asset value, reflecting confidence in its intangible assets like intellectual property and pipeline potential. Alternative valuation metrics show a price-to-sales ratio of 3.59 and an EV/EBITDA of 26.41, suggesting that investors are willing to pay a high multiple for every dollar of revenue and earnings, typical for growth-oriented biotechnology firms. The stock has traded between a 52-week low of $13.40 and a 52-week high of $28.35, and without the current share price explicitly provided in the facts, the relative position is defined by this established volatility range. The beta value of 0.83 suggests that the stock's price volatility is lower than the broader market, moving less aggressively than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth over the last year was 9.4%, while earnings growth was 86.2%, indicating that profitability is expanding at a rate far faster than top-line sales. This divergence implies improved operational leverage or margin expansion, as the company is generating significantly more profit growth than revenue growth. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all net income back into research, development, and commercialization rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by capital appreciation potential driven by earnings acceleration and pipeline milestones rather than current income generation.